FDA Announces Recall of Hydrochlorothiazide Tablets
The U.S. Food and Drug Administration (FDA) has announced that Unichem Pharmaceuticals is voluntarily recalling one lot of Hydrochlorothiazide Tablets 25 mg 1000-count bottle to the consumer level, as a Clopidogrel tablet was found in a bottle of the product. Patients who mistakenly take a Clopidogrel tablet are at an increased risk for bleeding and/or bruising and could experience uncontrolled blood pressure or edema, due to a missed dose of Hydrochlorothiazide.
According to the FDA announcement, “the affected Hydrochlorothiazide tablets include Lot # GHYL15028 - expiration April 2018, and was distributed nationwide directly to wholesalers, retailers, and pharmacies from May 21 - 28, 2015.”
Clinical Topics: Cardiovascular Care Team, Statins
Keywords: Blood Pressure, Blood Pressure Determination, Edema, Hemorrhage, Hydrochlorothiazide, Pharmacies, Ticlopidine, United States Food and Drug Administration
< Back to Listings